Dr Nathan on Updated Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma
Source: OncLive, November 2023
Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the 3-year survival data from the phase 3 IMCgp100-202 trial (NCT03070392) of tebentafusp-tebn (Kimmtrak) in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma.
The randomized, open-label IMCgp100-202 study randomly assigned patients with metastatic uveal melanoma to receive tebentafusp vs the investigator’s choice of pembrolizumab (Keytruda), ipilimumab (Yervoy) or dacarbazine.
Previously reported data from the primary analysis of the trial, which focused on previously untreated patients, showed that tebentafusp improved OS compared with the investigator’s choice of treatment, with a hazard ratio (HR) of 0.51.